Breast CancerCancer TreatmentTargeted TherapyTriple-Negative Breast CancerWe present an interesting case of a 56-year-old female diagnosed with invasive high-grade triple-negative breast cancer, who developed diffuse liver metastases following lumpectomy and combination chemotherapy with docetaxel, doxorubicin...
ductal癌在原处和三倍消极乳腺癌的家史和风险在韩中国人口: 情形控制研究。 [translate] aPatients with triple negative breast cancer: is there an optimal adjuvant treatment? 有三倍消极乳腺癌的病人: 有没有一种优选的辅药治疗? [translate] 英语翻译 日语翻译 韩语翻译 德语翻译 法语翻译 俄语翻译 阿拉伯...
Triple-negativebreast cancer, or TNBC, affects 10–15% of patients with breast cancer in the US. TNBC is called "triple-negative" because the cancer lacks anestrogen receptor, aprogesterone receptor, and a HER2 (human epidermal growth factor) receptor. The absence of any of these receptors—r...
In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new ...
Triple-negative breast cancer is more aggressive than other forms. It’s more likely to have spread beyond your breast at the time it’s found, and there’s a higher chance it will come back within the first 3 years after treatment. It’s also more likely to be fatal within the first...
[translate] a[Triple negative breast cancer: a difficult disease to diagnose and treat]. (三倍消极乳腺癌: 诊断和对待的一种困难的疾病)。[translate]
Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least favourable outcomes. In the past few years, advances in omics technologies have shed light on the relevance of the...
Triple-negative breast cancer is an aggressive subtype of breast cancer that has limited treatment options when it does not respond to or progresses following standard anthracycline- and/or taxane-containing regimens. Research is now directed at identifying molecules that may be effective targets for ...
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Hemin sensitizes triple-negative breast cancer to metformin by degrading BACH1, a University of Chicago-led team has found. (nito100/iStock/Getty Images Plus) 而近日由芝加哥大学科学家团队通过细胞系和小鼠肿瘤模型的研究表明,将2种治疗糖尿病和卟啉症的药物-二甲双胍&血红素 -进行组合,可以抑制三阴性乳...